Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $9.9B | $2.6B | $1.3B | $2.0B | 7.1% | 2.2% | -20.8% |
| 2024 | $9.7B | $2.8B | $1.6B | $2.5B | 9.8% | -1.6% | 40.6% |
| 2023 | $9.8B | $2.0B | $1.2B | $1.2B | 7.8% | -3.3% | -61.9% |
| 2022 | $10.2B | $4.4B | $3.0B | $1.1B | 22.7% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 9,890.60 |
| Operating Revenue | 9,890.60 |
| Cost Of Revenue | 2,404.20 |
| Gross Profit | 7,486.40 |
| Operating Expense | 5,017.40 |
| Research And Development | 1,778.60 |
| Selling General And Administration | 2,433.60 |
| Total Expenses | 7,421.60 |
| Operating Income | 2,469 |
| Total Operating Income As Reported | - |
| EBITDA | 2,603.90 |
| Normalized EBITDA | 3,398.60 |
| EBIT | 1,824 |
| Interest Income | 125 |
| Interest Expense | 267.50 |
| Net Interest Income | -142.50 |
| Other Non Operating Income Expenses | 24.70 |
| Other Income Expense | -770 |
| Interest Income Non Operating | 125 |
| Interest Expense Non Operating | 267.50 |
| Net Non Operating Interest Income Expense | -142.50 |
| Pretax Income | 1,556.50 |
| Tax Provision | 263.60 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -134.59 |
| Net Income Continuous Operations | 1,292.90 |
| Net Income From Continuing And Discontinued Operation | 1,292.90 |
| Net Income From Continuing Operation Net Minority Interest | 1,292.90 |
| Net Income | 1,292.90 |
| Net Income Common Stockholders | 1,292.90 |
| Net Income Including Noncontrolling Interests | 1,292.90 |
| Normalized Income | 1,953.01 |
| Diluted NI Availto Com Stockholders | 1,292.90 |
| Basic Average Shares | 146.50 |
| Diluted Average Shares | 147.10 |
| Reconciled Depreciation | 779.90 |
| Reconciled Cost Of Revenue | 2,139.30 |
| Total Unusual Items | -794.70 |
| Total Unusual Items Excluding Goodwill | -794.70 |
| Minority Interests | 0 |
| Earnings From Equity Interest Net Of Tax | - |
| Special Income Charges | -746.40 |
| Gain On Sale Of Business | - |
| Other Special Charges | 611.30 |
| Impairment Of Capital Assets | 52.90 |
| Restructuring And Mergern Acquisition | 82.20 |
| Gain On Sale Of Security | -48.30 |
| Depreciation Amortization Depletion Income Statement | 515 |
| Depreciation And Amortization In Income Statement | 515 |
| Gain On Sale Of Ppe | - |
| Other Operating Expenses | 290.20 |
| Amortization | 515 |
| Amortization Of Intangibles Income Statement | 515 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Biogen Inc.this co. | BIIB | $29.0B | 22.43↑ premium | 1.59 | 7.1% | 12.51 |
| Zoetis Inc. | ZTS | $33.3B | 12.47 | 10.01 | 80.2% | 9.90 |
| IQVIA Holdings Inc. | IQV | $31.2B | 22.93 | 4.80 | 20.9% | 13.04 |
| Centene Corporation | CNC | $31.0B | -4.64 | 1.55 | -33.4% | -6.54 |
| GE HealthCare Technologies Inc. | GEHC | $29.0B | 13.93 |
| - |
| - |
| - |
| - |
| 2.80 |
| 20.1% |
| 9.24 |
| ResMed Inc. | RMD | $28.2B | 20.12 | 4.72 | 23.5% | 14.47 |
| DexCom, Inc. | DXCM | $28.0B | 33.49 | 10.20 | 30.5% | 20.97 |
| Mettler-Toledo International Inc. | MTD | $23.9B | 27.44 | - | -3676.8% | 20.87 |
| Insmed Incorporated | INSM | $22.7B | -17.81 | 30.77 | -172.8% | - |
| Peer Median | - | 17.03 | 4.80 | 20.5% | 13.04 | |